PredicineCARE™ Liquid Biopsy Assay Featured in NEJM as Pivotal Tool in Roche’s Phase III Itovebi Breast Cancer Trial
PredicineCARE™ was utilized to identify and enroll patients with PIK3CA-mutated metastatic breast cancer in China, a key component contributing to the FDA’s approval of Inavolisib in the U.S. on October 10, 2024. HAYWARD, Calif., Nov. 04, 2024 (GLOBE …